Author
TUM Klinikum
Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.
31 papers
Recent·Most cited
Andreas Wutz, R. Abt, F. Schmidt, T. Hartmann, M. Rogalla, M. Seifter, Nathan Weisz
The paper shows brain-body synchrony acts as a temporal gate for conscious access across sensory systems by aligning neural activity with cardiac and respiratory cycles.
bioRxiv · May 12, 2026 · PreprintNeuroscience
D. Bakırdöğen, Kıvanç Görgülü, J. Xin, L. Richter, Sonia Alcalá, Laura Ruíz-Cañas, C. Dai, Katrin J. Frank, Nan Wu, Kalliope Nina Diakopoulos, H. Ozturk, Deniz Demircioğlu, Katja Peschke, R. Ranjan, Francesca Fusco, , Hana Algül
This study identifies c-Rel as a driver of pancreatic cancer metastasis by promoting EMT, ECM remodeling, and resistance to isolation stress through fibronectin-integrin signaling.
Molecular Cancer · Dec 15, 2025Peer-reviewedCancer Biology
F. Zhang, F. Schmidt, F. Muecksch, Z. Wang, A. Gazumyan, M. C. Nussenzweig, C. Gaebler, M. Caskey, T. Hatziioannou, P. D. Bieniasz
This study examines how SARS-CoV-2 spike glycosylation affects viral function and neutralization sensitivity to antibodies.
bioRxiv · Jun 30, 2023Microbiology
A. Billet, J. Hadjerci, T. Tran, P. Kessler, J. Ulmer, G. Mourier, M. Ghazarian, A. Gonzalez, R. Thai, P. Urquia, A.-C. Vanbaelen, A. Meola, I. Fernandez, S. Deville-Foillard, E. MacDonald, , L. Johannes
This paper develops a synthetic delivery vector for mucosal vaccination that induces mucosal immunity and CD8+ T cell responses in mice.
bioRxiv · May 15, 2023Biochemistry
L. Witte, V. Baharani, F. Schmidt, Z. Wang, A. Cho, R. Raspe, M. C. Guzman-Cardozo, F. Muecksch, C. Gaebler, M. Caskey, M. C. Nussenzweig, T. Hatziioannou, P. D. Bieniasz
The paper shows that epistasis reduces the genetic barrier for SARS-CoV-2 variants to escape broadly neutralizing antibodies by enabling resistance through combinations of mutations.
bioRxiv · Aug 17, 2022Microbiology
Z. Wang, P. Zhou, F. Muecksch, A. Cho, T. B. Tanfous, M. Canis, L. Witte, B. Johnson, R. Raspe, F. Schmidt, E. Bednarski, J. DaSilva, V. Ramos, S. Zong, M. Turroja, , M. C. Nussenzweig
This study compares memory B cell responses after Delta and Omicron BA.1 breakthrough infections versus mRNA vaccine doses, finding that Delta infection boosts overall memory B cell potency and breadth, while Omicron infection only enhances strain-specific responses.
bioRxiv · Aug 11, 2022Immunology
L. Jia, M. Rafiq, L. Radosa, P. Hortschansky, C. A. Cunha, Z. Cseresnyes, T. Krueger, F. Schmidt, T. Heinekamp, M. Strassburger, B. Loeffler, T. Doenst, J. F. Lacerda, A. Campos, M. T. Figge, , A. A. Brakhage
This study identifies HscA as an effector protein from Aspergillus fumigatus that redirects phagosomes to the recycling expulsion pathway by anchoring p11, affecting susceptibility to invasive pulmonary aspergillosis.
bioRxiv · May 18, 2022Cell Biology
A. Cho, F. Muecksch, Z. Wang, T. Ben Tanfous, J. DaSilva, R. Raspe, B. Johnson, E. Bednarski, V. Ramos, D. Schaefer-Babajew, I. Shimeliovich, J. Dizon, K.-H. Yao, F. Schmidt, K. G. Millard, , M. C. Nussenzweig
This study compares memory B cell responses after single-dose Ad26.COV2.S and mRNA vaccines, finding lower quantities but comparable neutralizing quality in Ad26.COV2.S recipients.
bioRxiv · Mar 31, 2022Immunology
M. Goldmann, F. Schmidt, Z. Cseresnyes, T. Orasch, S. Jahreis, S. Hartung, M. T. Figge, M. von Lilienfeld-Toal, T. Heinekamp, A. A. Brakhage
This study shows that stomatin is necessary for dectin-1 accumulation in phagosomal membranes and for macrophage activity against Aspergillus fumigatus.
bioRxiv · Feb 25, 2022Microbiology
F. Muecksch, Z. Wang, A. Cho, C. Gaebler, T. Ben Tanfous, J. DaSilva, E. Bednarski, V. Ramos, S. Zong, B. Johnson, R. Raspe, D. Schaefer-Babajew, I. Shimeliovich, M. Daga, K.-H. Yao, , M. Nussenzweig
This study shows that a third mRNA vaccine dose increases the potency and breadth of SARS-CoV-2 neutralizing antibodies, particularly against the Omicron variant, through the expansion and evolution of memory B cells.
bioRxiv · Feb 14, 2022 · PreprintImmunology
F. Schmidt, H. B. Abdesselem, K. Suhre, m. u. Sohail, M. Al-Nesf, I. Bensmail, F. Mashod, H. Sarwath, J. Bernhardt, T.-M. Tan, P. E. Morris, E. J. Schenck, D. Price, N. Vaikath, V. Mohamed-Ali, , O. M. A. El-Agnaf
This study identifies increased autoantibody responses against male reproductive system proteins in COVID-19 ICU patients using immunome protein-array technology.
bioRxiv · Feb 9, 2022Immunology
Z. Wang, F. Muecksch, A. Cho, C. Gaebler, H.-H. Hoffmann, V. Ramos, S. Zong, M. Cipolla, B. Johnson, F. Schmidt, J. DaSilva, E. Bednarski, T. B. Tanfous, R. Raspe, K. Yao, , M. C. Nussenzweig
The paper identifies conserved neutralizing epitopes on the N-terminal domain of SARS-CoV-2 spike proteins using NTD-specific probes and characterizes antibodies that neutralize multiple variants.
bioRxiv · Feb 1, 2022 · PreprintImmunology
K. J. Ciecielski, A. Mulero-Sanchez, A. Berninger, L. R. Canas, A. Bosma, K. Gorgulu, N. Wu, K. N. Diakopoulos, E. Kaya-Aksoy, D. A. Ruess, D. Kabacaoglu, F. Schmidt, L. Heinemann, Y. Fan, B. Thijssen, , S. Mainardi
This paper investigates the combination of SHP2 and ERK inhibition as a treatment for KRAS-driven pancreatic ductal adenocarcinoma, showing synergistic anticancer effects and tumor regression in mouse models.
bioRxiv · Dec 14, 2021 · PreprintCancer Biology
F. Schmidt, Y. Weisblum, M. Rutkowska, D. Poston, J. Da Silva, F. Zhang, E. Bednarski, A. Cho, D. Schaefer-Babajew, C. Gaebler, M. Caskey, M. C. Nussenzweig, T. Hatziioannou, P. D. Bieniasz
This study shows that multiple neutralizing epitopes in SARS-CoV-2 spike proteins are targeted by polyclonal antibodies, and 20 mutations can confer resistance, but vaccinated and infected individuals' plasma neutralizes these resistant variants and diverse sarbecoviruses.
bioRxiv · Aug 6, 2021Microbiology
A. Cho, F. Muecksch, D. Schaefer-Babajew, Z. Wang, S. Finkin, C. Gaebler, V. Ramos, M. Cipolla, P. Mendoza, M. Agudelo, E. Bednarski, J. DaSilva, I. Shimeliovich, J. Dizon, M. Daga, , M. C. Nussenzweig
This study examines memory B cell evolution 5 months after mRNA vaccination in naive individuals, finding increased neutralizing activity but no further breadth or potency, and higher overall plasma neutralizing potency compared to natural infection.
bioRxiv · Jul 29, 2021Immunology
Z. Wang, F. Muecksch, D. Schaefer-Babajew, S. Finkin, C. Viant, C. Gaebler, H.- H. Hoffmann, C. O. Barnes, M. Cipolla, V. Ramos, T. Y. Oliveira, A. Cho, F. Schmidt, J. D. Silva, E. Bednarski, , M. C. Nussenzweig
This study shows that convalescent individuals with or without vaccination maintain neutralizing activity and memory B cells against SARS-CoV-2 for up to one year, with vaccination enhancing breadth and potency against variants.
bioRxiv · May 7, 2021Immunology
C. A. Jette, A. A. Cohen, P. N. P. Gnanapragasam, F. Muecksch, Y. E. Lee, K. E. Huey-Tubman, F. Schmidt, T. Hatziioannou, P. D. Bieniasz, M. C. Nussenzweig, A. P. West, J. R. Keeffe, P. Bjorkman, C. O. Barnes
The paper identifies two class 4 anti-RBD antibodies from COVID-19 donors that broadly neutralize zoonotic sarbecoviruses and SARS-CoV-2 variants with high potency.
bioRxiv · Apr 23, 2021Immunology
F. D. Mast, P. C. Fridy, N. E. Ketaren, J. Wang, E. Y. Jacobs, J. P. Olivier, T. Sanyal, K. R. Molloy, F. Schmidt, M. Rutkowska, Y. Weisblum, L. M. Rich, E. R. Vanderwall, N. Dambrauskas, V. Vigdorovich, , M. P. Rout
This paper presents a large repertoire of high-affinity nanobodies against SARS-CoV-2 Spike protein with potent neutralization properties and resistance to viral variants.
bioRxiv · Apr 8, 2021Biochemistry
A. J. Greaney, T. N. Starr, C. O. Barnes, Y. Weisblum, F. Schmidt, M. Caskey, C. Gaebler, M. Agudelo, S. Finkin, Z. Wang, D. Poston, F. Muecksch, T. Hatziioannou, P. D. Bieniasz, D. F. Robbiani, , J. D. Bloom
The paper maps mutations in SARS-CoV-2 spike RBD that escape binding by three antibody classes and finds that plasma escape maps closely resemble those of a single antibody class targeting site E484.
bioRxiv · Mar 17, 2021Microbiology
F. Muecksch, Y. Weisblum, C. Barnes, F. Schmidt, D. Schaefer-Babajew, J. Lorenzi, A. Flyak, A. DeLaitsch, K. Huey-Tubman, S. Hou, C. Schiffer, C. Gaebler, Z. Wang, J. Da Silva, D. Poston, , P. Bieniasz
This study examines how somatic mutations in SARS-CoV-2 antibodies affect their neutralization potency, breadth, and resistance to escape mutations across six antibody lineages.
bioRxiv · Mar 7, 2021 · PreprintMicrobiology
Z. Wang, F. Schmidt, Y. Weisblum, F. Muecksch, C. O. Barnes, S. Finkin, D. Schaefer-Babajew, M. Cipolla, C. Gaebler, J. A. Lieberman, T. Y. Oliveira, Z. Yang, M. E. Abernathy, K. E. Huey-Tubman, A. Hurley, , M. C. Nussenzweig
This study examines antibody and memory B cell responses to mRNA vaccines against SARS-CoV-2 and assesses their effectiveness against emerging variants.
Nature · Feb 10, 2021Peer-reviewedImmunology
C. Gaebler, Z. Wang, J. C. C. Lorenzi, F. Muecksch, S. Finkin, M. Tokuyama, A. Cho, M. Jankovic, D. Schaefer-Babajew, T. Y. Oliveira, M. Cipolla, C. Viant, C. O. Barnes, A. Hurley, M. Turroja, , R. Patel
This study examines the evolution of antibody immunity to SARS-CoV-2 over time, finding that memory B cells evolve with increased potency and resistance to mutations.
bioRxiv · Nov 3, 2020Immunology
A. Schaefer, F. Muecksch, J. C. C. Lorenzi, S. R. Leist, M. Cipolla, S. Bournazos, F. Schmidt, A. Gazumyan, R. S. Baric, D. F. Robbiani, T. Hatziioannou, J. V. Ravetch, P. D. Bieniasz, M. C. Nussenzweig, T. P. Sheahan
This study evaluates the in vivo protective efficacy of SARS-CoV-2 monoclonal antibodies, finding that in vitro potency does not always predict in vivo activity and that effector function and combinations are critical for protection.
bioRxiv · Sep 15, 2020Microbiology
Y. Weisblum, F. Schmidt, F. Zhang, J. DaSilva, D. Poston, J. C. C. Lorenzi, F. Muecksch, M. Rutkowska, H.-H. Hoffmann, E. Michailidis, C. Gaebler, M. Agudelo, A. Cho, Z. Wang, A. Gazumyan, , P. D. Bieniasz
The paper shows SARS-CoV-2 variants resistant to neutralizing antibodies can be selected and are present in circulating populations, suggesting the need for combination antibody therapies.
bioRxiv · Jul 21, 2020Microbiology
F. Schmidt, Y. Weisblum, F. Muecksch, H.-H. Hoffmann, E. Michailidis, J. C. C. Lorenzi, P. Mendoza, M. Rutkowska, E. Bednarski, C. Gaebler, M. Agudelo, A. Cho, Z. Wang, A. Gazumyan, M. Cipolla, , P. D. Bieniasz
The paper describes assays using pseudotyped and chimeric viruses to measure SARS-CoV-2 neutralizing antibody activity, showing correlation with authentic assays.
bioRxiv · Jun 8, 2020Microbiology
C. O. Barnes, A. P. West, K. Huey-Tubman, M. A. G. Hoffmann, N. G. Sharaf, P. R. Hoffman, N. Koranda, H. B. Gristick, C. Gaebler, F. Muecksch, J. C. Cetrulo Lorenzi, S. Finkin, T. Hagglof, A. Hurley, K. G. Millard, , P. J. Bjorkman
bioRxiv · May 28, 2020Immunology
I. Lui, X. X. Zhou, S. A. Lim, S. Elledge, P. Solomon, N. J. Rettko, B. S. Zha, L. L. Kirkemo, J. A. Gramespacher, J. Liu, F. Muecksch, J. C. C. Lorenzi, F. Schmidt, Y. Weisblum, D. F. Robbiani, , J. A. Wells
This study investigates the interaction between SARS-CoV-2 Spike and ACE2, showing that dimeric ACE2 binds with high affinity to Spike and blocks viral entry, with limited intra-Spike avidity.
bioRxiv · May 21, 2020 · PreprintBiochemistry
D. F. Robbiani, C. Gaebler, F. Muecksch, J. Cetrulo Lorenzi, Z. Wang, A. Cho, M. Agudelo, C. Barnes, S. Finkin, T. Hagglof, T. Oliveira, C. Viant, A. Hurley, K. Millard, R. Kost, , Nuss
The paper analyzes antibody responses in convalescent individuals, finding low neutralizing titers but rare potent RBD-specific antibodies with broad antiviral potential.
bioRxiv · May 13, 2020Immunology
T. Kueck, L.-M. Bloyet, E. Cassella, T. Zang, F. Schmidt, V. Brusic, G. Tekes, O. Pornillos, S. Whelan, P. D. Bieniasz
This study identifies TRIM69 as an IFN-induced antiviral factor that inhibits VSVIND replication by targeting its phosphoprotein P through a novel transcriptional inhibition mechanism.
bioRxiv · Jun 27, 2019Microbiology
F. Schmidt, A. Thywissen, M. Röcker, C. Cunha, Z. Cseresnyes, H. Schmidt, S. Galiani, M. H. Gräler, G. Chamilos, J. F. Lacerda, A. Campos, C. Eggeling, T. Figge, T. Heinekamp, S. G. Filler, , A. A. Brakhage
This study shows that flotillin-dependent lipid rafts are essential for phagolysosomal function against fungal infections, with implications for human susceptibility to aspergillosis.
bioRxiv · Apr 12, 2019Microbiology